![Multi-parameter lead optimization to give an oral checkpoint kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).]()
Multi-parameter lead optimization to give an oral checkpoint kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).Osborne, James D; Matthews, Thomas Peter; McHardy, Tatiana; Proisy, Nicolas; Cheung, Kwai-Ming Jack; Lainchbury, Michael; Brown, Nathan; Walton, Michael I; Eve, Paul D; Boxall, Katherine J.; Hayes, Angela; Henley, Alan T; Valenti, Melanie R; De Haven Brandon, Alexis K; Box, Gary; Jamin, Yann; Robinson, Simon P; Westwood, Isaac M; van Montfort, Rob Leon Marie; Leonard, Philip M; Lamers, Marieke BAC; Reader, John C.; Aherne, G Wynne; Raynaud, Florence I; Eccles, Suzanne A.; Garrett, Michelle D; Collins, Ian · Journal of Medicinal Chemistry · 2016